Constanza Lourdes Andaur Navarro

Constanza Lourdes Andaur Navarro

Auto-generated profile, based on publicly available information

Constanza Lourdes Andaur Navarro

Department Data Science & Biostatistics, Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in BMJ
Verified
Journal Article
Open access
PDF file
KMKarel G M Moons
Karel G M Moons
JDJohanna A A Damen
Johanna A A Damen
TKTabea Kaul
Tabea Kaul
LHLotty Hooft
Lotty Hooft
CNConstanza Andaur Navarro
Constanza Andaur Navarro
MSMaarten van Smeden
Maarten van Smeden
The Prediction model Risk Of Bias ASsessment Tool (PROBAST) is used to assess the quality, risk of bias, and applicability of prediction models or algorithms and of prediction model/algorithm studies. Since PROBAST’s introduction in 2019, much progress has been made in the methodology for prediction modelling and in the use of artificial intelligence, including machine learning, techniques. An update to PROBAST-2019 is thus needed. This article describes the development of PROBAST+AI. PROBAST+AI consists of two distinctive parts: model development and model evaluation. For model development, PROBAST+AI users assess quality and applicability using 16 targeted signalling questions. For model evaluation, PROBAST+AI users assess the risk of bias and applicability using 18 targeted signalling questions. Both parts contain four domains: participants and data sources, predictors, outcome, and analysis. Applicability of the prediction model is rated for the participants and data sources, predictors, and outcome domains. PROBAST+AI may replace the original PROBAST tool and allows all key stakeholders (eg, model developers, AI companies, researchers, editors, reviewers, healthcare professionals, guideline developers, and policy organisations) to examine the quality, risk of bias, and applicability of any type of prediction model in the healthcare sector, irrespective of whether regression modelling or AI techniques are used.

9 July 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
GCGary S Collins
Gary S Collins
PDPaula Dhiman
Paula Dhiman
CNConstanza L Andaur Navarro
Constanza L Andaur Navarro
JMJie Ma
Jie Ma
LHLotty Hooft
Lotty Hooft
KMKarel Gm Moons
Karel Gm Moons
Introduction The Transparent Reporting of a multivariable prediction model of Individual Prognosis Or Diagnosis (TRIPOD) statement and the Prediction model Risk Of Bias ASsessment Tool (PROBAST) were both published to improve the reporting and critical appraisal of prediction model studies for diagnosis and prognosis. This paper describes the processes and methods that will be used to develop an extension to the TRIPOD statement (TRIPOD-artificial intelligence, AI) and the PROBAST (PROBAST-AI) tool for prediction model studies that applied machine learning techniques. Methods and analysis TRIPOD-AI and PROBAST-AI will be developed following published guidance from the EQUATOR Network, and will comprise five stages. Stage 1 will comprise two systematic reviews (across all medical fields and specifically in oncology) to examine the quality of reporting in published machine-learning-based prediction model studies. In stage 2, we will consult a diverse group of key stakeholders using a Delphi process to identify items to be considered for inclusion in TRIPOD-AI and PROBAST-AI. Stage 3 will be virtual consensus meetings to consolidate and prioritise key items to be included in TRIPOD-AI and PROBAST-AI. Stage 4 will involve developing the TRIPOD-AI checklist and the PROBAST-AI tool, and writing the accompanying explanation and elaboration papers. In the final stage, stage 5, we will disseminate TRIPOD-AI and PROBAST-AI via journals, conferences, blogs, websites (including TRIPOD, PROBAST and EQUATOR Network) and social media. TRIPOD-AI will provide researchers working on prediction model studies based on machine learning with a reporting guideline that can help them report key details that readers need to evaluate the study quality and interpret its findings, potentially reducing research waste. We anticipate PROBAST-AI will help researchers, clinicians, systematic reviewers and policymakers critically appraise the design, conduct and analysis of machine learning based prediction model studies, with a robust standardised tool for bias evaluation. Ethics and dissemination Ethical approval has been granted by the Central University Research Ethics Committee, University of Oxford on 10-December-2020 (R73034/RE001). Findings from this study will be disseminated through peer-review publications. PROSPERO registration number CRD42019140361 and CRD42019161764.

20 October 2021 in BMJ
Verified
Journal Article
Open access
PDF file
CNConstanza L Andaur Navarro
Constanza L Andaur Navarro
JDJohanna A A Damen
Johanna A A Damen
TTToshihiko Takada
Toshihiko Takada
SNSteven W J Nijman
Steven W J Nijman
PDPaula Dhiman
Paula Dhiman
LHLotty Hooft
Lotty Hooft
Objective To assess the methodological quality of studies on prediction models developed using machine learning techniques across all medical specialties. Design Systematic review. Data sources PubMed from 1 January 2018 to 31 December 2019. Eligibility criteria Articles reporting on the development, with or without external validation, of a multivariable prediction model (diagnostic or prognostic) developed using supervised machine learning for individualised predictions. No restrictions applied for study design, data source, or predicted patient related health outcomes. Review methods Methodological quality of the studies was determined and risk of bias evaluated using the prediction risk of bias assessment tool (PROBAST). This tool contains 21 signalling questions tailored to identify potential biases in four domains. Risk of bias was measured for each domain (participants, predictors, outcome, and analysis) and each study (overall). Results 152 studies were included: 58 (38%) included a diagnostic prediction model and 94 (62%) a prognostic prediction model. PROBAST was applied to 152 developed models and 19 external validations. Of these 171 analyses, 148 (87%, 95% confidence interval 81% to 91%) were rated at high risk of bias. The analysis domain was most frequently rated at high risk of bias. Of the 152 models, 85 (56%, 48% to 64%) were developed with an inadequate number of events per candidate predictor, 62 handled missing data inadequately (41%, 33% to 49%), and 59 assessed overfitting improperly (39%, 31% to 47%). Most models used appropriate data sources to develop (73%, 66% to 79%) and externally validate the machine learning based prediction models (74%, 51% to 88%). Information about blinding of outcome and blinding of predictors was, however, absent in 60 (40%, 32% to 47%) and 79 (52%, 44% to 60%) of the developed models, respectively. Conclusion Most studies on machine learning based prediction models show poor methodological quality and are at high risk of bias. Factors contributing to risk of bias include small study size, poor handling of missing data, and failure to deal with overfitting. Efforts to improve the design, conduct, reporting, and validation of such studies are necessary to boost the application of machine learning based prediction models in clinical practice. Systematic review registration PROSPERO CRD42019161764.

25 November 2022 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
CNConstanza L. Andaur Navarro
Constanza L. Andaur Navarro
JDJohanna A.A. Damen
Johanna A.A. Damen
MSMaarten van Smeden
Maarten van Smeden
TTToshihiko Takada
Toshihiko Takada
SNSteven W.J. Nijman
Steven W.J. Nijman
LHLotty Hooft
Lotty Hooft
We sought to summarize the study design, modelling strategies, and performance measures reported in studies on clinical prediction models developed using machine learning techniques. We search PubMed for articles published between 01/01/2018 and 31/12/2019, describing the development or the development with external validation of a multivariable prediction model using any supervised machine learning technique. No restrictions were made based on study design, data source, or predicted patient-related health outcomes. We included 152 studies, 58 (38.2% [95% CI 30.8-46.1]) were diagnostic and 94 (61.8% [95% CI 53.9-69.2]) prognostic studies. Most studies reported only the development of prediction models (n = 133, 87.5% [95% CI 81.3-91.8]), focused on binary outcomes (n = 131, 86.2% [95% CI 79.8-90.8), and did not report a sample size calculation (n = 125, 82.2% [95% CI 75.4-87.5]). The most common algorithms used were support vector machine (n = 86/522, 16.5% [95% CI 13.5-19.9]) and random forest (n = 73/522, 14% [95% CI 11.3-17.2]). Values for area under the Receiver Operating Characteristic curve ranged from 0.45 to 1.00. Calibration metrics were often missed (n = 494/522, 94.6% [95% CI 92.4-96.3]). Our review revealed that focus is required on handling of missing values, methods for internal validation, and reporting of calibration to improve the methodological conduct of studies on machine learning-based prediction models. PROSPERO, CRD42019161764.

13 January 2022 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
CNConstanza L. Andaur Navarro
Constanza L. Andaur Navarro
JDJohanna A. A. Damen
Johanna A. A. Damen
TTToshihiko Takada
Toshihiko Takada
SNSteven W. J. Nijman
Steven W. J. Nijman
PDPaula Dhiman
Paula Dhiman
LHLotty Hooft
Lotty Hooft
Background: While many studies have consistently found incomplete reporting of regression-based prediction model studies, evidence is lacking for machine learning-based prediction model studies. We aim to systematically review the adherence of Machine Learning (ML)-based prediction model studies to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Statement. Methods: We included articles reporting on development or external validation of a multivariable prediction model (either diagnostic or prognostic) developed using supervised ML for individualized predictions across all medical fields. We searched PubMed from 1 January 2018 to 31 December 2019. Data extraction was performed using the 22-item checklist for reporting of prediction model studies (www.TRIPOD-statement.org). We measured the overall adherence per article and per TRIPOD item. Results: Our search identified 24,814 articles, of which 152 articles were included: 94 (61.8%) prognostic and 58 (38.2%) diagnostic prediction model studies. Overall, articles adhered to a median of 38.7% (IQR 31.0–46.4%) of TRIPOD items. No article fully adhered to complete reporting of the abstract and very few reported the flow of participants (3.9%, 95% CI 1.8 to 8.3), appropriate title (4.6%, 95% CI 2.2 to 9.2), blinding of predictors (4.6%, 95% CI 2.2 to 9.2), model specification (5.2%, 95% CI 2.4 to 10.8), and model’s predictive performance (5.9%, 95% CI 3.1 to 10.9). There was often complete reporting of source of data (98.0%, 95% CI 94.4 to 99.3) and interpretation of the results (94.7%, 95% CI 90.0 to 97.3). Conclusion: Similar to prediction model studies developed using conventional regression-based techniques, the completeness of reporting is poor. Essential information to decide to use the model (i.e. model specification and its performance) is rarely reported. However, some items and sub-items of TRIPOD might be less suitable for ML-based prediction model studies and thus, TRIPOD requires extensions. Overall, there is an urgent need to improve the reporting quality and usability of research to avoid research waste. Systematic review registration: PROSPERO, CRD42019161764.

11 November 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
CNConstanza L Andaur Navarro
Constanza L Andaur Navarro
JDJohanna A A G Damen
Johanna A A G Damen
TTToshihiko Takada
Toshihiko Takada
SNSteven W J Nijman
Steven W J Nijman
PDPaula Dhiman
Paula Dhiman
LHLotty Hooft
Lotty Hooft
Introduction Studies addressing the development and/or validation of diagnostic and prognostic prediction models are abundant in most clinical domains. Systematic reviews have shown that the methodological and reporting quality of prediction model studies is suboptimal. Due to the increasing availability of larger, routinely collected and complex medical data, and the rising application of Artificial Intelligence (AI) or machine learning (ML) techniques, the number of prediction model studies is expected to increase even further. Prediction models developed using AI or ML techniques are often labelled as a ‘black box’ and little is known about their methodological and reporting quality. Therefore, this comprehensive systematic review aims to evaluate the reporting quality, the methodological conduct, and the risk of bias of prediction model studies that applied ML techniques for model development and/or validation. Methods and analysis A search will be performed in PubMed to identify studies developing and/or validating prediction models using any ML methodology and across all medical fields. Studies will be included if they were published between January 2018 and December 2019, predict patient-related outcomes, use any study design or data source, and available in English. Screening of search results and data extraction from included articles will be performed by two independent reviewers. The primary outcomes of this systematic review are: (1) the adherence of ML-based prediction model studies to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD), and (2) the risk of bias in such studies as assessed using the Prediction model Risk Of Bias ASsessment Tool (PROBAST). A narrative synthesis will be conducted for all included studies. Findings will be stratified by study type, medical field and prevalent ML methods, and will inform necessary extensions or updates of TRIPOD and PROBAST to better address prediction model studies that used AI or ML techniques. Ethics and dissemination Ethical approval is not required for this study because only available published data will be analysed. Findings will be disseminated through peer-reviewed publications and scientific conferences. Systematic review registration PROSPERO, CRD42019161764.